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Background: Anal intraepithelial neoplasia grade 2 (AIN2) and AIN grade 3 (AIN3) are commonly grouped
together as high grade squamous intraepithelial lesions (HSIL). We assessed risk factors for HSIL-AIN2
and HSIL-AIN3 in a cohort of homosexual men.
Methods: At the baseline visit in the Study for the Prevention of Anal Cancer (SPANC), all men completed
a questionnaire and underwent anal swabbing for cytology and HPV genotyping, followed by high re-
solution anoscopy.
Results: Composite-HSIL prevalence was 47% and 32% among 220 HIV-positive and 396 HIV-negative
men, respectively. HSIL-AIN3 (37.7% versus 24.7%; po0.001), but not HSIL-AIN2 (9.5% versus 7.6%;
p¼0.395) was more common in HIV-positive men. Recent receptive anal partners (p-trend¼0.045), and
increasing number of high-risk (HR)-HPV types (p-trendo0.001) were associated with HSIL-AIN2.
Lifetime receptive partners (p-trendo0.001), HIV status (OR 1.74; 95% CI: 1.05–2.87) and HPV16 (OR
3.00; 95% CI: 1.56–5.75) were associated with HSIL-AIN3. HPV16 was the most common HR-HPV type
detected in men with HSIL-AIN3, both HIV-negative (61.1%) and HIV-positive (54.9%). HPV16 was less
commonly detected in men with HSIL-AIN2.
Conclusions: Grouping HSIL-AIN2 and HSIL-AIN3 as HSIL may mask considerable heterogeneity in anal
cancer risk. Given the strong link between HPV16 and anal cancer, men with HSIL-AIN3 and HPV16 are
likely to be at greatest risk of cancer.
Crown Copyright & 2016 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).evier B.V. This is an open access a
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Grulich).1. Introduction
Population-based screening programs have been successful in
reducing human papillomavirus (HPV)-associated cervical cancer
incidence and mortality. As an understanding that HPV also causes
anal squamous intraepithelial lesions (ASIL) and anal cancer [1–3]
has emerged, some researchers have advocated a similar anal
cancer screening program among the highest risk groups, namely
men who have sex with men (MSM) and people with HIV [4].
Although anal and cervical high grade SIL (HSIL) share clinical
and histological similarities [5], aspects of the epidemiology andrticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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different. In particular, anal HSIL prevalence in MSM greatly ex-
ceeds that of cervical HSIL in women in the general population. In
a recent meta-analysis, HSIL prevalence in MSM was 29.1% in HIV-
positive, and 21.5% in HIV-negative men [6]. HSIL prevalence in
MSM is so high that it is clear that most cases will never progress
to anal cancer.
HSIL can be graded by the proportion of involvement of the
epithelial layer as intraepithelial neoplasia grade 2 (IN2) or 3 (IN3)
[7]. In the cervix, HSIL-cervical IN2 (HSIL-CIN2) is more likely to
regress than HSIL-CIN3 [8]. However as the combined prevalence
of CIN2 and CIN3 does not exceed 2% in a screening population [9]
and both may progress to cancer, CIN2 and CIN3 are usually
grouped together for treatment purposes [7]. The grouping of
HSIL-AIN2 and HSIL-AIN3 as anal HSIL is also generally accepted
for the clinical management. However, in contrast to the cervix,
there have been no reported studies which have separately ex-
amined characteristics of HSIL-AIN2 and HSIL-AIN3.
We analysed baseline data from a predominantly community-
recruited cohort of MSM in Sydney, Australia, to investigate risk
factors for anal HSIL, and for HSIL-AIN 2 and HSIL-AIN3 separately.2. Materials and methods
2.1. Study population
The Study of Prevention of ANal Cancer (SPANC) is an ongoing
prospective study of HIV-positive and HIV-negative MSM, based in
Sydney, Australia. Participants were recruited mainly from com-
munity-based settings. In addition, about 35% of HIV-positive and
5% of HIV-negative men were recruited through medical clinics.
Eligible participants were men aged 35 years or over who reported
sex with another man in their lifetime (any homosexual contact).
Participants were excluded if they were unable to understand
English, unable to attend scheduled follow-up visits or were un-
willing to undergo high resolution anoscopy (HRA), had a bleeding
disorder or were on anti-coagulation medications (except aspirin
and other non-steroidal anti-inﬂammatory drugs). Men who had
previously received HRA or those with a history of anal cancer
were also excluded from the study [10]. The study was approved
by the St Vincent's Hospital Human Research Ethics Committee
(Sydney, Australia) and all participants gave written informed
consent. The study protocol and the study's main objectives have
been described in detail previously [10].
At the baseline visit, all men underwent anal swabbing for
cytology and HPV genotyping immediately followed by high re-
solution anoscopy (HRA) and directed biopsy of any suspected
HPV-associated abnormalities. Participants also completed de-
tailed audio computer-assisted self-interviews (ACASI QDS, Be-
thesda, MD) [10], which collected information about potential risk
factors such as lifetime and recent (in the previous six months)
sexual practices and tobacco use. Additional information was
sought from HIV-positive participants on CD4 T-lymphocyte count,
HIV viral load and AIDS-deﬁning illnesses.
2.2. HPV detection, anal cytology and HRA
The clinical and laboratory procedures performed in this study
have been described in detail previously [10]. In brief, a saline-
moistened Dacron swab was blindly inserted 3–5 cm into the anal
canal and then gradually withdrawn while applying ﬁrm cir-
cumferential pressure to the wall of the anal canal for approxi-
mately one minute. The swab was then agitated in a vial con-
taining PreservCyt (Hologic Corporation, Bedford, MA, USA). Prior
to cytological processing, an aliquot of the medium wastransferred to a separate tube for HPV testing. The remaining
sample was used for cytological analysis. If the anal swab were
deemed unsatisfactory for cytological evaluation, a repeat anal
collection was performed approximately two weeks from the ﬁrst.
A ‘satisfactory’ slide was deﬁned as having at least 2000 nucleated
squamous cells.
The HRA was performed immediately after the anal swab [10].
Following insertion of a plastic anoscope and application of acetic
acid, the anal canal was visualised under high-resolution magni-
ﬁcation with further application of acetic acid (3% initially [10], but
changed in January 2015 to 5% in response to evolving opinion that
the higher concentration may allow better visualisation of SIL
[11]), followed by Lugol's iodine, to help identify any HPV-asso-
ciated abnormalities [11]. Abnormalities which were visually
suggestive of ASIL were biopsied for histological assessment. Men
who had no visual abnormalities did not undergo biopsy.
The samples were transferred to a pathology laboratory (Dou-
glass Hanly Moir Pathology, Sydney, Australia) for processing and
assessment. Reporting of cytology results was performed accord-
ing to The Bethesda System TBS [12]. Reporting of biopsy results
was performed in accordance with criteria, terminology and re-
commendations of the Lower Anogenital Squamous Terminology
(LAST) Project [13], as described previously [10]. In particular,
when a diagnosis of HSIL-AIN2 was proposed based on histo-
morphologic features on hematoxylin and eosin (H&E) stained
slides, immunostaining for p16-INK4A (p16) was performed. Only
strong uniform p16 immunostaining of the basal layer was con-
sidered positive. Positivity for p16 coupled with H&E features of
AIN2 were both required for the diagnosis of HSIL-AIN2. If the p16
result was negative, the lesion was downgraded to LSIL or negative
for SIL, depending on other criteria. Immunostaining for p16 was
not performed in making diagnoses of straightforward LSIL or
HSIL–AIN3. If multiple biopsies were taken, the result with the
highest grade of disease was used for analysis [14].
HPV testing was performed on the anal PreservCyt specimens
using the Roche LINEAR ARRAY (Roche Molecular Systems, Ala-
meda, CA, US) to detect 37 individual HPV types with modiﬁca-
tions as previously described [15]. As an in-house modiﬁcation,
samples that were negative for HPV and internal control were
retested with half the volume of eluted DNA in order to reduce the
inhibition due to high bacterial DNA content.
2.3. Statistical analysis
Given the acknowledged limitations in ASIL diagnosis of both
histology and cytology [16] ASIL disease classiﬁcation was based
on composite endpoints of the most severe cytology or histology
diagnoses, as outlined in Table 1. The exact binomial method was
used to calculate 95% conﬁdence intervals (CIs) for prevalence
values. Odds ratios (ORs) and 95% CIs were estimated using logistic
regression. Univariate and adjusted analyses were performed to
identify risk factors for HSIL compared to men without ASIL, with
further stratiﬁed analysis of risk factors for HSIL-AIN2 and HSIL-
AIN3. Men in the composite-LSIL and ASC-H categories were ex-
cluded from this analysis. Sensitivity analyses restricted to histo-
logically conﬁrmed HSIL were also performed.
For each of the above outcomes, we evaluated the following
factors: age, HIV status, smoking exposure (never, past, current
with r10 pack years of exposure, and current with 410 packs
years of exposure), HPV16 status, number of HR-HPV types and the
number of lifetime and recent (previous six months) receptive
anal intercourse partners with and without a condom. Given the
causal role of HPV in HSIL, the overall effect of sexual behaviours
was ﬁrst examined without considering HPV status. Sexual beha-
viour variables which were associated with each outcome at
po0.100 were considered in the initial multivariate model. Only
Table 1
Baseline prevalence of composite cytology-histology anal squamous intraepithelial lesions among 616 men in the Study of the Prevention of Anal Cancer, stratiﬁed by HIV
status.
ASIL category Deﬁnition All men (N¼616) HIV-Negative men (n¼396) HIV-Positive men (N¼220) p-Value
n % (95% CI) n % (95% CI) n % (95% CI)
Composite-
negative
Visually normal HRA with no biopsy taken, or no
evidence of ASIL on any biopsy or cytology
183 29.7 (26.2–33.4) 135 34.1 (29.6–38.9) 48 21.8 (16.8–27.8) 0.001
Composite-LSIL LSIL or ASCUS cytology and/or LSIL histology as
the highest grade of ASIL
155 25.2 (21.9–28.8) 97 24.5 (20.5–29.0) 58 26.4 (20.9–32.6) 0.609
Composite-ASC-
H
ASC-H cytology and no HSIL (rLSIL) on
histology
46 7.5 (5.6–9.8) 36 9.1 (6.6–12.4) 10 4.5 (2.5–8.3) 0.040
Composite-HSIL HSIL detected by either cytology or histology 232 37.7 (33.9–41.6) 128 32.3 (27.9–37.1) 104 47.3 (40.7–53.9) o0.001
Composite HSIL-
AIN2
HSIL-AIN2 on cytology and/or AIN2 on histology
withoutAIN3 on either
51 8.3 (6.3–10.7) 30 7.6 (5.3–10.6) 21 9.5 (6.3–14.2) 0.395
Composite HSIL-
AIN3
HSIL-AIN3 on cytology or histology 181 29.4 (2.6–33.1) 98 24.7 (20.7–29.3) 83 37.7 (31.5–44.4) o0.001
Abbreviations: ASIL: Anal squamous intraepithelial lesion; HRA: High resolution anoscopy; AIN: Anal Intraepithelial neoplasia; ASC-US: Atypical squamous cells of un-
determined signiﬁcance; LSIL: low-grade squamous intraepithelial lesions; ASC-H: Atypical-squamous cells cannot exclude high-grade squamous intraepithelial lesion; HSIL:
high-grade squamous intraepithelial lesion; HSIL-AIN2 and HSIL-AIN3; HPV: Human papillomavirus; HR-HPV: High-risk HPV.
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with age, HIV status and smoking in the ﬁnal multivariate analyses
(Table 3). In separate analyses we examined the association of
increasing number of HR-HPV types with HSIL, HSIL-AIN2 and
HSIL-AIN3 (Table 4) adjusting for HPV16, age, HIV status and
smoking (Table 4, Stratum A). Given the known strong relationship
between HPV 16 and anal cancer risk [2], we also conducted this
analysis stratiﬁed by HPV16 status (Table 4, Stratum B and Stratum
C). Among HIV-positive men, factors relating to HIV disease in-
cluding, nadir and current CD4þ T-cell counts, HIV viral load, anti-
retroviral treatment (ART) status, and history of AIDS-deﬁning
illness, were assessed individually adjusted for age, smoking sta-
tus, HPV16 status and number of HR-HPV types (Table 5). Data
analyses were performed using STATA version 14 (Stata Corpora-
tion, College Station, TX, US).3. Results
Among the 617 participants enrolled from September 2010 to
August 2015, 397 (64.3%) were HIV-negative and 220 (35.7%) were
HIV-positive. The median age at enrolment was 49 years (IQR: 43–
56), with no difference by HIV status (p¼0.786). Nearly all men
(95.3%) identiﬁed as gay or homosexual, 2.9% identiﬁed as bisexual
and 1.1% identiﬁed as “other”. Four (0.7%) men identiﬁed as het-
erosexual. Among HIV-positive participants, the median time since
their HIV diagnoses was 15 years (range: 0–30). Most (93.6%) were
currently on ART, reported an undetectable HIV viral load (89.5%)
and had a CD4 count of more than 350 cells/ml (88.0%).
Cytology data were available for all 617 participants. Among the
HIV-negative, 22 (5.5%) men had repeatedly unsatisfactory anal
swabs, 169 (42.6%) had no ASIL, 61 (15.4%) ASC-US, 19 (4.8%) LSIL,
60 (15.1%) ASC-H, 13 (3.3%) HSIL-AIN2 and 53 (13.4%) HSIL-AIN3.
Among the HIV-positive, 7 (3.2%) men had repeatedly un-
satisfactory anal swabs, 72 (32.7%) had no ASIL, 42 (19.1%) ASC-US,
28 (12.7%) LSIL, 28 (12.7%) ASC-H, 8 (3.6%) HSIL-AIN2 and 35
(15.9%) HSIL-AIN3. HRA data were available for 616 participants.
One HIV-negative man was excluded because he did not tolerate
HRA. Among the HIV-negative, 193 (48.7%) men had a visually
normal HRA or had biopsies showing no evidence of ASIL, 100
(25.3%) LSIL, 29 (7.3%) HSIL-AIN2 and 74 (18.7%) HSIL-AIN3. Among
the HIV-positive, 72 (32.7%) men had a visually normal HRA or had
biopsies showing no evidence of ASIL, 55 (25.0%) LSIL, 20 (9.1%)
HSIL-AIN2 and 73 (33.2%) HSIL-AIN3. One HIV-positive man who
had a superﬁcially invasive anal cancer arising from an HSIL lesion
was classiﬁed as HSIL in these analyses. The baseline prevalence ofcomposite-ASIL endpoints is presented in Table 1, stratiﬁed by HIV
status. Hereafter, SIL outcomes referred to are composite end-
points unless otherwise speciﬁed.
In univariate analysis HSIL was signiﬁcantly associated with
being HIV-positive (po0.001), having more lifetime receptive
partners with (p-trendo0.001) and without a condom (p-
trendo0.001), and having more receptive partners with
(p¼0.022) and without (p¼0.004) a condom in the previous six
months (Table 2). In stratiﬁed analysis, both HSIL-AIN2 and HSIL-
AIN3 were signiﬁcantly associated with HIV positivity (p¼0.040
and po0.001, respectively) and with having more lifetime re-
ceptive partners without a condom (p-trendo0.018 and
p-trendo0.001, respectively). In addition, HSIL-AIN2 was sig-
niﬁcantly associated with having more receptive partners with (p-
trendo0.001) and without (p-trendo0.001) a condom in the
previous six months (Table 2).
In multivariate analyses (Table 3) behavioural risk factors that
were independently associated with HSIL included HIV positivity
(p¼0.035), and having more lifetime receptive partners with (p-
trend¼0.032) and without (p-trend¼0.001) a condom. Factors
that were independently associated with HSIL-AIN2 included re-
ceptive practices with (p-trend¼0.044) and without (p-tren-
d¼0.045) a condom in the previous six months. For HSIL-AIN3,
HIV positivity (p¼0.031) and having more lifetime receptive
partners without a condom (po0.001) were signiﬁcantly asso-
ciated (Table 3).
In separate analyses examining the association of HSIL, HSIL-
AIN2 and HSIL-AIN3 with increasing number of HR-HPV types
(Table 4 Stratum A), HSIL was strongly associated with increasing
number of HR-HPV types (p-trendo0.001) and HPV16 positivity
(p¼0.028). This was also the case for HSIL-AIN2 and HSIL-AIN3
examined separately (p-trendo0.001 for each) (Table 4 Stratum
A). HSIL-AIN3 was strongly associated with HPV16 positivity
(po0.001). In contrast, HSIL-AIN2 had a negative association with
HPV16 (OR; 0.35, 95% CI: 0.12–1.00; p¼0.050).
In analyses stratiﬁed by HPV16 status, when the analysis was
limited to HPV16 positive men, HSIL-AIN2, but not HSIL-AIN3,
remained signiﬁcantly associated with increasing number of HR-
HPV types (p-trend¼0.033) (Table 4, Stratum B). Among HPV16
negative (other HR-HPV positive) men, both HSIL-AIN2 and HSIL-
AIN3 remained strongly associated with increasing number of HR-
HPV types (p-trend¼0.001 and p-trend¼0.004, respectively)
(Table 4, Stratum C). HPV16 was the most commonly detected HR-
HPV type detected in men with HSIL-AIN3, both in HIV-negative
(61.1%) and HIV-positive (54.9%) (p¼0.401) men. In contrast,
HPV16 was less commonly detected in men with HSIL-AIN2,
Table 2
Univariate analysis of risk factors for prevalent composite-HSIL in the Study of the Prevention of Anal Cancer, overall and stratiﬁed by composite-AIN2 and composite-AIN3 diagnoses.
Composite-HSIL versus composite-negativea (n¼415) Composite-AIN2 versus composite-negative b
(n¼234)
Composite-AIN3 versus Composite-negative c (n¼364)
Variable n (%) OR (95% CI) p-Value n (%) OR (95% CI) p-Value n (%) OR (95% CI) p-Value
Age 35–44 years 74/131 (56.5) 1.00 0.577 21/78 (26.9) 1.00 0.113 53/110 (48.2) 1.00 0.991
45–54 years 89/161 (55.3) 0.95 (0.60–1.52) 18/90 (20.0) 0.68 (0.33–1.40) 71/143 (49.7) 1.06 (0.64–1.75)
55–64 years 52/84 (61.6) 1.25 (0.71–2.20) 10/42 (23.8) 0.85 (0.35–2.03) 42/74 (56.8) 1.41 (0.78–2.56)
65þ years 17/39 (43.6) 0.60 (0.29–1.23) 2/24 (8.3) 0.25 (0.05–1.18) 15/37 (40.5) 0.73 (0.34–1.57)
HIV status HIV-negative 128/263 (48.7) 1.00 o0.0011 30/165 (18.2) 1.00 0.0401 98/233 (42.1) 1.00 o0.0011
HIV-positive 104/152 (68.4) 2.29 (1.50–3.47) 21/69 (30.4) 1.97 (1.03–3.76) 83/131 (63.4) 2.38 (1.53–3.70)
Smoking status Never 120/223 (53.8) 1.00 0.104 26/129 (20.2) 1.00 0.586 94/197 (47.7) 1.00 0.084
Past 76/138 (55.1) 1.05 (0.69–1.61) 18/80 (22.5) 1.15 (0.58–2.25) 58/120 (48.3) 1.03 (0.65–1.61)
Current r10PY 12/19 (63.2) 1.47 (0.56–3.88) 5/12 (41.7) 2.83 (0.83–9.64) 7/14 (50.0) 1.10 (0.37–3.24)
Current 410PY 24/35 (68.6) 1.87 (0.88–4.01) 2/13 (15.4) 0.72 (0.15–3.45) 22/33 (66.7) 2.19 (1.01–4.76)
HPV16 status Negative 114/273 (41.8) 1.00 o0.0011 40/199 (20.1) 1.00 0.0931 74/233 (31.8) 1.00 o0.0011
Positive 114/136 (83.8) 7.23 (4.31–12.11) 11/33 (33.3) 1.99 (0.89–4.43) 103/125 (82.4) 10.06 (5.88–17.20)
Number of HR-HPV types 0 25/134 (18.7) 1.00 o0.001 9/118 (7.6) 1.00 o0.001 16/125 (12.8) 1.00 o0.001
1 55/98 (56.1) 5.58 (3.09–10.06) 10/53 (18.9) 2.82 (1.07–7.41) 45/88 (51.1) 7.13 (3.65–13.94)
2 66/84 (78.6) 16.00 (8.11–31.51) 17/35 (48.6) 11.44 (4.43–29.56) 49/67 (73.1) 18.55 (8.73–39.38)
3þ 82/93 (88.2) 32.50 (15.16–
69.83)
15/26 (57.7) 16.52 (5.88–46.41) 67/78 (85.9) 41.49 (18.17–
94.76)
Lifetime receptive partners with a condom 0–1 5/24 (20.8) 1.00 o0.001 0/19 o0.001 5/24 (20.8) 1.00 o0.001
2–5 19/52 (36.5) 2.19 (0.69–6.96) 2/35 (5.7) N/A 17/50 (34.0) 1.96 (0.61–6.27)
6–10 25/42 (59.5) 5.59 (1.58–19.75) 4/21 (19.1) N/A 21/38 (55.3) 4.69 (1.33–16.53)
410 176/286 (61.5) 6.08 (2.15–17.22) 45/155 (29.0) N/A 131/241 (54.4) 4.53 (1.60–12.79)
Lifetime receptive partners without a
condom
0–1 18/63 (28.6) 1.00 o0.001 4/49 (8.2) 1.00 0.018 14/59 (23.7) 1.00 o0.001
2–5 52/105 (49.5) 2.45 (1.24–4.86) 18/71 (25.4) 3.82 (1.17–12.53) 34/87 (39.1) 2.06 (0.97–4.37
6–10 56/85 (65.9) 4.83 (2.25–10.36) 5/34 (14.7) 1.94 (0.47–7.95) 51/80 (63.8) 5.65 (2.48–12.88)
410 106/162 (65.4) 4.73 (2.41–9.30) 24/80 (30.0) 4.82 (1.49–15.57) 82/138 (59.4) 4.71 (2.27–9.78)
Previous six months, receptive partners
with a condom
None 91/180 (50.6) 1.00 0.022 13/102 (12.8) 1.00 o0.001 78/167 (46.7) 1.00 0.194
One 40/70 (57.1) 1.30 (0.75–2.28) 8/38 (21.1) 1.83 (0.68–4.87) 32/62 (51.6) 1.22 (0.68–2.19)
2–5 53/94 (56.4) 1.26 (0.76–2.09) 15/56 (26.8) 2.50 (1.08–5.83) 38/79 (48.1) 1.06 (0.62–1.81)
45 48/71 (67.6) 2.04 (1.14–3.66) 15/38 (39.5) 4.46 (1.78–11.17) 33/56 (58.9) 1.64 (0.88–3.04)
Previous six months, receptive partners
without a condom
None 103/197 (52.3) 1.00 0.004 16/110 (14.6) 1.00 o0.001 87/181 (48.1) 1.00 0.054
One 62/121 (51.2) 0.96 (0.61–1.51) 14/73 (19.2) 1.39 (0.63–3.08) 48/107 (44.9) 0.88 (0.54–1.42)
2–5 39/62 (62.9) 1.55 (0.86–2.79) 12/35 (34.3) 3.07 (1.25–7.54) 27/50 (54.0) 1.27 (0.68–2.38)
45 28/35 (80.0) 3.65 (1.49–8.93) 9/16 (56.3) 7.55 (2.27–25.09) 19/26 (73.1) 2.93 (1.16–7.42)
Numbers do not always add up to column totals because of small amounts of missing data.
PY: Pack Years.
1 Score test of homogeneity, else the p-values presented are score test for trend of odds.
a Comparing men with composite negative result (n¼183) to men with HSIL detected on by either cytology or histology (n¼232).
b Comparing men with composite negative result (n¼183) to men with HSIL-AIN2 on cytology and/or AIN2 on histology without a diagnosis of AIN3 on either (n¼51).
c Comparing men with composite negative result (n¼183) to men with HSIL-AIN3 on cytology or histology (n¼181).
Men in the composite-LSIL (n¼155) and composite-ASC-H (n¼55) were excluded from analyses of risk factors.
Row percentages presented.
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Table 3
Multivariate analysis of sexual behaviour risk factors for prevalent composite-HSIL in the Study of the Prevention of Anal Cancer, overall and stratiﬁed by composite-AIN2 and composite-AIN3 diagnoses.
Composite-HSIL versus composite-negativea
(n¼415)
Composite-AIN2 versus composite-negativeb
(n¼234)
Composite-AIN3 versus Composite-negativec (n¼364)
Variable n (%) Adjusted OR (95%
CI)
p-Value n (%) Adjusted OR (95%
CI)
p-Value n (%) Adjusted OR (95% CI) p-Value
HIV status HIV-negative 128/263 (48.7) 1.00 0.0351 30/165 (18.2) 1.00 0.4361 98/233 (42.1) 1.00 0.0311
HIV-positive 104/152 (68.4) 1.69(1.03–2.76) 21/69 (30.4) 1.35 (0.64–2.85) 83/131 (63.4) 1.74 (1.05–2.87)
Lifetime receptive partners with a
condom
0–1 5/24 (20.8) 1.00 0.032
2–5 19/52 (36.5) 1.79 (0.66–4.87)
6–10 25/42 (59.5) 2.24 (0.82–6.11)
410 176/286 (61.5) 2.51 (1.03–6.08)
Lifetime receptive partners without a
condom
0–1 18/63 (28.6) 1.00 0.001 14/59 (23.7) 1.00 o0.001
2–5 52/105 (49.5) 2.24 (1.13–4.42) 34/87 (39.1) 2.08 (0.99–4.36)
6–10 56/85 (65.9) 3.92 (1.90–8.12) 51/80 (63.8) 5.07 (2.37–10.85)
410 106/162 (65.4) 3.26 (1.62–6.56) 82/138 (59.4) 3.61 (1.74–7.49)
Previous six months, receptive partners
with a condom
None 13/102 (12.8) 1.00 0.044
One 8/38 (21.1) 1.67 (0.62–4.52)
2–5 15/56 (26.8) 2.06 (0.84–5.00)
45 15/38 (39.5) 2.66 (0.96–7.39)
Previous six months, receptive partners
without a condom
None 16/110 (14.6) 1.00 0.045
One 14/73 (19.2) 1.26 (0.56–2.82)
2–5 12/35 (34.3) 1.84 (0.66–5.08)
45 9/16 (56.3) 4.16 (1.13–15.27)
1 Score test of homogeneity, else the p-values presented are score test for trend of odds.
a Comparing men with composite negative result (n¼183) to men with HSIL detected on by either cytology or histology (n¼232).
b Comparing men with composite negative result (n¼183) to men with HSIL-AIN2 on cytology and/or AIN2 on histology without a diagnosis of AIN3 on either (n¼51).
c Comparing men with composite negative result (n¼183) to men with HSIL-AIN3 on cytology or histology (n¼181).
Men in the composite-LSIL (n¼155) and composite-ASC-H (n¼55) were excluded from analyses of risk factors.
Adjusted for age, smoking exposure and the variables presented in the table.
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Table 4
Association of the number of HR-HPV with prevalent composite-HSIL, among HR-HPV positive men, in the Study of the Prevention of Anal Cancer, overall and stratiﬁed by
composite-AIN2 and composite-AIN3 diagnoses.
Composite-HSIL versus composite-negativea
(n¼415)
Composite-AIN2 versus composite-negativeb
(n¼234)
Composite-AIN3 versus Composite-
negativec (n¼364)
Variable n (%) Adjusted OR
(95% CI)
p-Value n (%) Adjusted
OR (95% CI)
p-Value n (%) Adjusted
OR (95% CI)
p-Value
Stratum A: Among all HR-HPV positive men
HPV16 Negative 89/13 (64.0) 1.00 0.0281 31/81 (38.3) 1.00 0.0501 58/108 (53.7) 1.00 0.0011
Positive 114/136 (83.8) 2.02
(1.08–3.79)
11/33 (33.3) 0.35
(0.12–1.00)
103/125 (82.4) 2.91
(1.52–5.57)
Number of
HR-HPV
types
1 55/98 (56.1) 1.00 o0.001 10/53 (18.9) 1.00 o0.001 45/88 (51.1) 1.00 o0.001
2 66/84 (78.6) 2.70
(1.39–5.26)
17/35 (48.6) 4.85
(1.80–13.09)
49/67 (73.1) 2.23
(1.10–4.53)
3þ 82/93 (88.2) 4.30
(1.94–9.53)
15/26 (57.5) 10.23
(3.04–34.43)
67/78 (85.9) 3.58
(1.57–8.14)
Stratum B: Among HPV16 positive men
Number of
HR-HPV
types
1 23/30 (76.7) 1.00 0.071 1/8 (12.5) 1.00 0.033 22/29 (75.9) 1.00 0.111
2 27/35 (77.1) 1.01
(0.33–3.28)
2/10 (20.0) 2.16
(0.15–30.51)
25/33 (75.8) 0.96
(0.29–3.14)
3þ 64/71 (90.0) 2.73
(0.83–8.92)
8/15 (53.0) 10.44
(0.93–
117.13)
56/63 (88.9) 2.43
(0.74–7.99)
Stratum C: Among HPV16 negative but other HR-HPV positive men
Number of
HR-HPV
types
1 32/68 (47.1) 1.00 o0.001 9/45 (20.0) 1.00 0.001 23/59 (39.0) 1.00 0.004
2 39/49 (79.6) 4.35
(0.87–10.11)
15/25 (60.0) 5.97
(2.02–17.68)
24/34 (70.6) 3.62
(1.46–8.99)
3þ 18/22 (81.8) 4.98
(1.52–16.32)
7/11 (63.4) 7.26
(1.71–30.80)
11/15 (73.3) 4.19
(1.19–14.81)
All analyses presented were adjusted for HIV status, age, smoking exposure and the variables presented in the table.
1 Score test of homogeneity, else the p-values presented are score test for trend of odds.
a Comparing men with composite negative result to men with HSIL detected on by either cytology or histology.
b Comparing men with composite negative result to men with HSIL-AIN2 on cytology and/or AIN2 on histology without a diagnosis of AIN3 on either.
c Comparing men with composite negative result to men with HSIL-AIN3 on cytology or histology; Men in the composite-LSIL (n¼155) and composite-ASC-H (n¼55)
were excluded from analyses of risk factors.
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(p¼0.286).
Among HIV-positive men, neither HSIL-AIN2 nor HSIL-AIN3
outcomes were signiﬁcantly associated with most recent CD4þ
T-cell count, HIV viral load, ART treatment status or a history of
AIDS deﬁning illness. A non-signiﬁcant trend was observed be-
tween HSIL-AIN3 and lower nadir CD4þ T-cell count (p-tren-
d¼0.080) (Table 5).4. Discussion
In this cohort of HIV-positive and HIV-negative homosexual
men, the baseline prevalence of composite-HSIL was 47% and 32%,
respectively. Prevalence of HSIL-AIN3, but not HSIL-AIN2, was
signiﬁcantly higher in HIV-positive men. Signiﬁcant predictors of
composite HSIL-AIN2 included higher numbers of recent (but not
lifetime) receptive anal intercourse partners, and increasing
number of HR-HPV types. In contrast, predictors of composite
HSIL-AIN3 included higher numbers of lifetime (but not recent)
receptive anal intercourse partners, HIV status and HPV16 detec-
tion. These data suggest that risk of HSIL-AIN2 is associated with
recent sexual behaviour, while HSIL-AIN3 is associated with HIV
positivity and lifetime sexual exposures suggesting chronic, long-
standing HR-HPV infection, particularly with HPV16. Given the
strong link between HPV16 and anal cancer, men with HSIL-AIN3
and HPV16 are likely to be at greatest risk of anal cancer.
Substantial research has been reported on the relationship
between HPV infection and HSIL-CIN2 and HSIL-CIN3 in women.
HPV infection is most common in young women, who have highernumber of recent sexual partners [17]. The time between incident
HPV infection and appearance of HSIL can be short. HSIL has been
diagnosed within two years of sexual debut with no difference by
HSIL grade (HSIL-CIN2 or HSIL-CIN3) [18–20]. In young, sexually
active women, approximately 40% of HSIL-CIN2 lesions will re-
solve without treatment, and HSIL-CIN2 caused by HR-HPV types
other than HPV16 is particularly likely to regress [8]. Our results
suggest that HSIL-AIN2 in homosexual men is similarly related to
recent sexual behaviour and infection with HR-HPV types other
than HPV16. Many homosexual men continue to have multiple
sexual partners well into older age, and hence are likely to have
higher rates of newly acquired HPV infections and of HSIL related
to recent infection [21,22].
The proportion of histological HSIL cases which were HSIL-
AIN2 in SPANC, of 8% [16], was somewhat lower than the 13–35%
reported in recent studies [23–25]. We believe that this may reﬂect
the strict use of the LAST diagnostic criteria in our study. We
stained all possible HSIL-AIN2 diagnoses with p16, and down-
graded (to LSIL or negative for LSIL) those cases which did not
have strong uniform staining of the basal layer. We believe it is
critical that studies in the ﬁeld state precisely whether LAST
guidelines broadly, and those regarding p16 staining speciﬁcally,
have been used. Otherwise, direct comparison between studies is
difﬁcult.
The majority of HSIL diagnosed (78%) were HSIL-AIN3. HSIL-
AIN3 was associated with lifetime sexual risk, suggesting chronic,
longstanding HR-HPV infection. In the cervix, rates of progression
to cancer are higher for HSIL-CIN3 than for HSIL-CIN2 [7]. Among
HSIL-CIN3 lesions, there is substantial heterogeneity in risk of
progressing to cervical cancer depending on the causative HR-HPV
Table 5
Multivariate analysis of HIV factors associated with prevalent composite-HSIL among HIV-positive men in the Study of the Prevention of Anal Cancer, overall and stratiﬁed by composite-AIN2 and composite-AIN3 diagnoses.
Composite-negative versus Composite-HSILa (n¼152) Composite-negative versus Composite-AIN2b (n¼69) Composite-negative versus Composite-AIN3c (n¼131)
Variable n (%) Adjusted OR (95% CI) p-Value n (%) Adjusted OR (95% CI) p-Value n (%) Adjusted OR (95% CI) p-Value
Nadir CD4þ T-cell count Z500 12/20 (60.0) 1.00 0.107 3/11 (27.3) 1.00 0.592 9/17 (52.9) 1.00 0.080
200–500 38/61 (62.3) 1.10 (0.39–3.10) 9/32 (28.3) 1.04 (0.21–5.32) 29/52 (55.8) 1.12 (0.37–3.36)
o200 51/68 (75.0) 2.00 (0.70–5.71) 9/26 (34.6) 1.41 (0.30–6.67) 42/59 (71.2) 2.20 (0.72–6.64)
Result of last CD4þ T-cell
count
4500 57/94 (60.6) 1.00 0.181 10/47 (21.3) 1.00 0.324 47/84 (56.0 1.00 0.248
500–351 29/35 (82.9) 2.95 (1.02–8.52) 8/14 (57.1) 4.12 (1.05–16.01) 21/27 (77.8) 3.08 (0.98–9.69)
r350 11/15 (73.3) 1.70 (0.43–6.74) 3/7 (42.9) 2.68 (0.44–16.14) 8/12 (66.7) 1.05 (0.20–5.52)
Result of last HIV viral load
testd
Undetectable 90/132 (68.2) 1.00 0.669 17/59 (28.8) 1.00 0.216 73/115 (63.5) 1.00 0.695
Detectable 9/12 (75.0) 1.40 (0.30–6.63) 3/6 (50.0) 3.21 (0.51–20.38) 6/9 (66.7) 0.70 (0.12–4.18)
Currently on any ART No 5/7 (71.4) 1.00 0.754 2/4 (50.0) 1.00 0.373 3/5 (60.0) 1.00 0.666
Yes 99/145 (68.3) 0.74 (0.12–4.72) 19/65 (29.2) 0.37 (0.04–3.30) 80/126 (63.5) 1.56 (0.21–11.68)
History of AIDS-deﬁning
illness
No 66/102 (64.7) 1.00 0.319 16/52 (30.8) 1.00 0.768 50/86 (58.1) 1.00 0.175
Yes 36/48 (75.0) 1.55 (0.65–3.70) 5/17 (29.4) 0.82 (0.22–3.03) 31/43 (72.1) 1.89 (0.75–4.71)
a Comparing men with composite negative result (n¼48) to men with HSIL detected on by either cytology or histology (n¼104).
b Comparing men with composite negative result (n¼48) to men with HSIL-AIN2 on cytology and/or AIN2 on histology without a diagnosis of AIN3 on either (n¼21).
c Comparing men with composite negative result (n¼48) to men with HSIL-AIN3 on cytology or histology (n¼83). Adjusted for number of HR-HPV types and HPV16 detected on anal swab, age and smoking exposure.
d Undetectable viral load: o50 copies; Detectable viral load Z50 copies.
Men in the composite-LSIL (n¼155) and composite-ASC-H (n¼55) were excluded from analyses of risk factors.
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D.A. Machalek et al. / Papillomavirus Research 2 (2016) 97–105104type [15]. HPV16 is clearly the type with the highest carcinogenic
potential [26]. According to a recent global review, infection with
HPV16 accounts for 87% of HPV positive invasive anal canal can-
cers worldwide [3]. In our study, HPV16 was detected in 58% of
men with HSIL-AIN3. HPV16 was a strong predictor of composite
HSIL-AIN3 and this was independent of the presence of other HR-
HPV types. In view of the fact that the large majority of anal
cancers are caused by HPV16, men with HPV16 and HSIL-AIN3 are
likely to have a higher risk of anal cancer compared to those with
HSIL-AIN3 associated with other HR-HPV types.
We found a strong association between number of HR-HPV
types and risk of HSIL-AIN2 and HSIL-AIN3, consistent with a
previous report of risk factors for composite-HSIL [25], and this
remained strongly signiﬁcant even after adjusting for the presence
of HPV16. However, we found divergent results when we per-
formed an analysis stratiﬁed by the presence of HPV16. Among
HPV16 negative men, we found that increasing number of HR-HPV
types was strongly associated with HSIL-AIN2 and HSIL-AIN3 risk.
On the other hand, among HPV16 positive men, we found in-
creasing number of HR-HPV types was associated with HSIL-AIN2,
but not HSIL-AIN3 risk. This may indicate that HSIL-AIN2 is driven
largely by non-HPV16 infections, whereas HSIL-AIN3 is most
commonly due to HPV16. The absence of a signiﬁcant effect of
increasing number of HPV types in HPV16 positive men argues
against a biological effect of interaction between HPV types on
HSIL-AIN3 risk as has been similarly demonstrated in the cervix
[27,28].
We found that HIV-positive men were at higher risk of HSIL-
AIN3, but not of HSIL-AIN2. MSM with HIV have a much higher
risk of anal cancer than HIV negative MSM [6,29], and our ﬁnding
of higher HSIL-AIN3 is entirely consistent with this pattern. In our
study decreasing nadir and current CD4þ T-cell count were not
signiﬁcantly associated with prevalent HSIL-AIN3. A signiﬁcant
relationship has been found by others [30,31].
This study has several limitations. First, these baseline data are
cross-sectional, so our ability to draw conclusions about the nat-
ural history of HSIL-AIN2 and HSIL-AIN3 is limited. However
SPANC is a three year prospective study, and future reports will
allow such longitudinal analyses. Second, the small sample size of
HIV-positive men limits the statistical power of the analysis to
detect potential associations between makers of immune function.
Third, HPV testing was based on ThinPrep aliquot collected prior to
cytological processing, and not on HPV detected within individual
HSIL lesions. We did not detect HR-HPV in ThinPrep residuum in 9
(17.7%) men with HSIL-AIN2 and 16 (9.0%) men with HSIL-AIN3.
There are three likely explanations for this given our use of com-
posite cytology and histology endpoints. First, p16 staining was
used to conﬁrm histological but not cytological HSIL-AIN2. Among
menwith HSIL-AIN2 on cytology only, misclassiﬁcation of a benign
cytological mimic, speciﬁcally immature metaplasia as HSIL is
possible [32,33]. Second, among men with HSIL on histology only,
the anal swab may have missed an HSIL lesion during sampling,
therefore missing the associated (causative) HPV type. Last, in-
fection with LR-HPV types may account for small proportion of
HSIL. LR-HPV types particularly HPV6 and HPV11 have been as-
sociated with a small proportion of anal cancers [34].
A strength of the study was that recruitment was mostly
community-based and likely to be representative of the target
screening population of HIV-positive and HIV-negative MSM. The
great majority identiﬁed as homosexual or gay. In addition, biopsy
reporting was performed in accordance with the LAST Project [13],
limiting potential misclassiﬁcation of histological HSIL. Also, there
was a very high degree of inter-rater reliability and intra-rater
repeatability in histological diagnosis in the study [35]. Finally, the
limited sensitivity of anal cytology and HRA to detect HSIL was
addressed by using a composite cytology-histology endpoint.While this is a more accurate measure of disease burden, we re-
cognise that histologically conﬁrmed HSIL is ultimately the clinical
outcome of interest. Sensitivity analyses were performed repeat-
ing the risk factor and HPV analyses comparing men with histo-
logical-AIN2 and histological-AIN3 to those who were ASIL nega-
tive, this did not affect the main study ﬁndings (data not shown).
In summary, we found an extremely high prevalence of HSIL in
homosexual men, about four-ﬁfths of which was the higher grade
lesion, HSIL-AIN3. Of these, just over half (58%) had detectable
HPV16, comprising 17% of all men enrolled in the study. While the
combination of HSIL-AIN2 and HSIL-AIN3 as HSIL may be required
for pathology reporting for clinical management purposes, in
homosexual men it probably masks considerable heterogeneity in
true anal cancer risk. Given the fact that HPV16 causes the great
majority of anal cancer and the widespread availability of HPV
genotyping assays, incorporation of testing for HPV16 in men with
HSIL may identify those at highest risk of anal cancer. Large, high-
quality prospective studies are required to inform whether HPV16
status is a useful marker of anal cancer risk.Conﬂict of interest statement
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